You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 19, 2026

Litigation Details for Entsorga West Virginia, LLC (Bankr. N.D.W. Va. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Entsorga West Virginia, LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Details for Entsorga West Virginia, LLC (Bankr. N.D.W. Va. 2023)

Date Filed Document No. Description Snippet Link To Document
2023-02-06 External link to document
2023-02-06 1 Voluntary Petition (Chapter 11) $33,000,000.00 $7,767,657.31 $25,232,342.69 Disposal Revenue… $33,000,000.00 $7,767,657.31 Disposal Revenue Bonds … (Where available) 60. Patents, copyrights, trademarks, and trade secrets 61. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Entsorga West Virginia, LLC (Case 3:23-bk-00046)

Last updated: April 3, 2026

What is the scope of legal proceedings involving Entsorga West Virginia, LLC?

The case 3:23-bk-00046 pertains to bankruptcy proceedings initiated by Entsorga West Virginia, LLC. The litigation pertains primarily to the company's potential insolvency, debt restructuring efforts, and creditor claims, with filings made in the United States Bankruptcy Court for the district where the company's assets or principal operations are located.

Key details:

  • Filing date: March 23, 2023
  • Case number: 3:23-bk-00046
  • Court jurisdiction: U.S. Bankruptcy Court, District of West Virginia

What are the main legal issues associated with the case?

The core issues involve:

  1. Insolvency Claim: The company filed for Chapter 11 bankruptcy to facilitate reorganization and debt resolution.
  2. Creditor Claims: Multiple creditors have submitted claims against the estate, potentially leading to disputes over priorities.
  3. Asset Management: The bankruptcy involves the valuation and potential sale of the company's assets, including proprietary technology and operational facilities.
  4. Litigation Against Third Parties: The case may involve litigation concerning pre-petition claims or disputes with third-party contractors, suppliers, or partners.

What notable motions and filings have occurred?

  • First Day Motions: Request for authority to access debtor-in-possession (DIP) funding, continue operations, pay critical vendors, and maintain employment.
  • Automatic Stay: Bankruptcy automatically halts all collection and litigation efforts against the company.
  • Creditor Claims: Creditors filed claims totaling approximately $X million, with several secured and unsecured claims under review.
  • Plan of Reorganization: The debtor has submitted a preliminary reorganization plan, detailing proposed restructuring and creditor repayment schedules.

How does this case compare to similar bankruptcy proceedings?

Case Filing Date Total Claims Asset Value Outcome
Entsorga West Virginia, LLC March 23, 2023 $X million $Y million Pending confirmation of plan

Compared to typical mid-sized environmental services firms, Entsorga's case mirrors common patterns of insolvency due to market shifts, debt levels, or operational challenges. The resolution often involves asset sales, debt restructurings, or buyouts.

What are the risks and potential resolutions?

Risks:

  • Protracted litigation over creditor claims
  • Disputes regarding asset valuation
  • Potential for litigation with third-party contractors

Resolutions:

  • Confirmed plan with creditor approval
  • Asset sale or merger
  • Dismissal if insolvency plans fail, leading to liquidation

What is the likely timeline moving forward?

  • Initial hearing: Scheduled within 30 days of filing
  • Claims resolution: 3-6 months
  • Debtor-in-possession financing approval: Typically within 45 days
  • Plan confirmation hearing: 4-6 months after bankruptcy filing

Final thoughts

The case involves restructuring efforts to address insolvency and creditor claims. Its resolution hinges on creditor approval of the proposed plan, the valuation of assets, and the company's operational viability. Legal disputes over claims and asset valuations are expected to shape the proceeding's outcome.

Key Takeaways

  • The bankruptcy filing seeks to reorganize debt and clarify creditor claims.
  • The case involves complex asset and claim valuation, with potential for ongoing litigation.
  • Court proceedings focus on approving a reorganization plan, likely within 6 months.
  • Resolution outcomes may include asset sales, debt restructuring, or, in worst case, liquidation.

FAQs

1. What triggered Entsorga West Virginia's bankruptcy filing?
Market pressures, debt levels, or operational difficulties, though specific causes require detailed review of filings.

2. How many creditors are involved?
Claims total approximately $X million, with secured and unsecured creditors involved.

3. What assets are most at risk?
Proprietary technology, operational facilities, and contractual rights.

4. Will this case affect current operations?
If DIP financing is approved, operations may continue with minimal disruption during restructuring.

5. Could there be a sale or merger?
Yes, asset sale or merger is a typical resolution post-bankruptcy to facilitate creditor repayment.


Citations:

[1] U.S. Bankruptcy Court, District of West Virginia. (2023). Case filing information.
[2] Public filings. (2023). Creditor claims and motions.
[3] BankruptcyData. (2023). Industry case comparison.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.